Why Is Kodiak Sciences (KOD) Up 10.5% Since Last Earnings Report?

A month has gone by since the last earnings report for Kodiak Sciences Inc. (KOD). Shares have added about 10.5% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Kodiak Sciences due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.How Have Estimates Been Moving Since Then?It turns out, estimates review have trended downward during the past month.The consensus estimate has shifted -10.35% due to these changes.VGM ScoresAt this time, Kodiak Sciences has a subpar Growth Score of D, though it is lagging a bit on the Momentum Score front with an F. Following the exact same course, the stock was allocated a grade of F on the value side, putting it in the lowest quintile for this investment strategy.Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Kodiak Sciences has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.Performance of an Industry PlayerKodiak Sciences is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Apellis Pharmaceuticals, Inc. (APLS), a stock from the same industry, has gained 17.7%. The company reported its results for the quarter ended March 2025 more than a month ago.Apellis Pharmaceuticals reported revenues of $166.8 million in the last reported quarter, representing a year-over-year change of -3.2%. EPS of -$0.74 for the same period compares with -$0.54 a year ago.For the current quarter, Apellis Pharmaceuticals is expected to post a loss of $0.44 per share, indicating a change of -57.1% from the year-ago quarter. The Zacks Consensus Estimate has changed -10.2% over the last 30 days.The overall direction and magnitude of estimate revisions translate into a Zacks Rank #4 (Sell) for Apellis Pharmaceuticals. Also, the stock has a VGM Score of F.7 Best Stocks for the Next 30 DaysJust released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.5% per year. So be sure to give these hand picked 7 your immediate attention. See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Kodiak Sciences Inc. (KOD): Free Stock Analysis Report Apellis Pharmaceuticals, Inc. (APLS): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks